YOLFTbeta
Century Therapeutics Inc

Century Therapeutics Inc

IPSC · NASDAQ · Healthcare / Biotechnology

1.65USD+0.02 (+1.23%)

Price History

Full chart

Market Stats

Previous Close1.63
Open1.62
Day Range1.57 – 1.68
52-Week Range0.435 – 3.04
Volume373.17K
Market Cap302.40M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.93
Dividend Yield0.00%
Beta1.60
50-Day Avg2.00
200-Day Avg2.05

About

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Brent Pfeiffenberger M.B.A., Pharm.D.
  • Employees78
  • Headquarters25 North 38th Street, Philadelphia, PA, United States, 19104, USA
  • Websitehttps://www.centurytx.com

Leadership

  • Dr. Brent Pfeiffenberger M.B.A., Pharm.D.President, CEO & Chairman · b. 1978
  • Dr. Gregory Russotti Ph.D.Chief Technology & Manufacturing Officer · b. 1967
  • Dr. Chad A. Cowan Ph.D.Chief Scientific Officer · b. 1972
  • Mr. Douglas Carr CPASenior VP of Finance & Operations, Principal Financial Officer and Secretary
  • Krista Kauppinen J.D., Ph.D.VP, General Counsel & Head of Intellectual Property
  • Ms. Megan BilsonChief People Officer
  • Michael Naso Ph.D.Senior VP of Cell Engineering
  • Ms. Elizabeth DevlinVP & Head of Development

Financials

Income Statement

Currency: USD2015-12-312016-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue950.79M470.32M001.06M5.20M2.23M6.59M109.16M
Growth (%)--50.53%-100.00%--+391.40%-57.01%+194.81%+1556.76%
Cost of Revenue888.81M467.84M249.00K1.75M4.58M10.07M13.04M13.30M13.10M
Gross Profit61.97M2.48M-249.00K-1.75M-4.58M5.20M2.23M6.59M96.06M
Gross Margin6.52%0.53%---433.08%100.00%100.00%100.00%88.00%
Operating Expense--19.78M47.42M90.30M139.03M148.78M144.73M111.10M
Operating Income---20.03M-49.18M-94.88M-133.83M-146.55M-138.14M-15.04M
Operating Margin-----8968.15%-2574.17%-6556.87%-2096.48%-13.78%
EBITDA---244.52M-51.44M-89.92M-121.20M-121.21M-111.47M3.45M
EBITDA Margin-----8499.43%-2331.24%-5423.18%-1691.79%3.16%
Net Income---244.77M-53.58M-95.82M-130.93M-136.67M-126.57M-9.58M
Net Income Margin-----9057.09%-2518.41%-6115.12%-1920.87%-8.78%
R&D11.44M9.09M14.27M39.68M75.65M97.17M92.71M107.24M95.67M
R&D as % of Total Revenue1.20%1.93%--7150.09%1869.07%4148.10%1627.62%87.64%
Interest Expense000381.00K1.27M1.10M540.00K0-
Interest Expense % of Total Revenue0.00%0.00%--120.51%21.25%24.16%0.00%-

Balance Sheet

Currency: USD2015-12-312016-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets844.70M758.00M90.90M106.78M437.38M486.54M360.69M353.22M223.70M
Total Liabilities484.99M575.54M182.75M213.19M41.14M183.81M175.94M191.85M64.77M
Total Equity359.71M182.46M-91.86M-106.41M396.24M302.74M184.75M161.36M158.94M
Cash208.00K21.47M44.06M27.21M56.45M84.27M47.32M58.44M61.85M
Total Debt---21.55M25.12M49.41M48.17M53.83M43.56M
Net Debt---44.06M-5.66M-31.33M-34.85M847.00K-4.61M-18.29M

Cash Flow

Currency: USD2015-12-312016-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow104.30M--16.17M-41.27M-89.00M14.05M-88.35M-110.14M-103.88M
Investing Cash Flow---19.83M-22.76M-298.34M-13.13M61.13M47.48M107.50M
Financing Cash Flow-98.09M74.84M47.69M417.77M27.16M-9.72M74.56M173.00K
Capital Expenditure29.39M11.12M2.46M9.82M44.97M30.60M13.74M154.00K848.00K
Free Cash Flow---18.63M-51.09M-133.97M-16.55M-102.08M-110.29M-104.72M
FCF to OCF--115.22%123.81%150.53%-117.79%115.55%100.14%100.82%

Earnings

Report DateMar 31, 2020Mar 31, 2021Jun 21, 2021Aug 12, 2021Nov 10, 2021Mar 17, 2022May 16, 2022Aug 11, 2022Nov 10, 2022Mar 16, 2023May 11, 2023Aug 9, 2023Nov 9, 2023Mar 14, 2024May 9, 2024Aug 8, 2024Nov 5, 2024Mar 19, 2025May 15, 2025Aug 14, 2025Nov 13, 2025Mar 12, 2026May 13, 2026Aug 12, 2026Nov 12, 2026
EPS Estimate0.000.00-0.44-0.38-0.42-0.48-0.54-0.50-0.60-0.59-0.52-0.54-0.49-0.55-0.45-0.50-0.45-0.45-0.31-0.37-0.38-0.30-0.17-0.11-0.12
EPS Actual-0.51-0.95-2.39-1.93-0.48-0.24-0.48-0.54-0.53-2.27-0.53-0.49-0.55-0.65-0.45-0.38-0.37-0.430.89-0.38-0.32-0.25-0.11-0.17-
Surprise---443.18%-407.89%-14.29%50.00%11.11%-8.00%11.67%-284.75%-1.92%9.26%-12.24%-18.18%0.00%24.00%17.78%4.44%387.10%-2.70%15.79%15.97%35.29%-54.55%-
Timing--After-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-After-hoursAfter-hoursPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap302.40M
Enterprise Value237.65M
Trailing P/E0.00
Forward P/E0.00
Price / Sales3.72
Price / Book1.37
EPS-0.93
Book Value1.29
Revenue (TTM)0
Gross Profit (TTM)-78.93M
EBITDA-95.22M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-49.65%
Return on Assets-23.51%
Shares Outstanding181.08M
Shares Float101.25M
Beta1.60
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 6 analystsTarget 4.75
  • Strong Buy
    3
  • Buy
    2
  • Hold
    1

Ownership Breakdown

Institutions
87.42%
Insiders
8.14%
Retail / Other
4.44%

Top Institutional Holders

  • RA Capital Management, LLC
    17.75M9.80%
  • TCG Crossover Management, LLC
    17.75M9.80%
  • Versant Venture Management LLC
    12.17M6.72%
  • Deep Track Capital, LP
    9.46M5.23%
  • RTW INVESTMENTS, LLC
    8.70M4.80%
  • COMMODORE CAPITAL LP
    8.70M4.80%
  • VR Adviser, LLC
    8.70M4.80%
  • Point72 Asset Management, L.P.
    5.96M3.29%
  • Vanguard Capital Management, LLC
    5.69M3.14%
  • Balyasny Asset Management LLC
    5.02M2.77%
  • Millennium Management LLC
    4.19M2.32%
  • Trails Edge Capital Partners, LP
    4.13M2.28%
  • Spruce Street Capital LP
    4.06M2.24%
  • Adage Capital Partners Gp LLC
    3.79M2.09%
  • Woodline Partners LP
    3.04M1.68%
  • Seven Fleet Capital Management LP
    2.95M1.63%
  • Two Sigma Investments LLC
    2.70M1.49%
  • Dafna Capital Management LLC
    2.40M1.33%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    4.34M2.40%
  • iShares Russell 2000 ETF
    2.98M1.64%